These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22727118)

  • 1. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.
    Hundeshagen A; Hecker M; Paap BK; Angerstein C; Kandulski O; Fatum C; Hartmann C; Koczan D; Thiesen HJ; Zettl UK
    J Neuroinflammation; 2012 Jun; 9():140. PubMed ID: 22727118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.
    Hecker M; Hartmann C; Kandulski O; Paap BK; Koczan D; Thiesen HJ; Zettl UK
    Mol Neurobiol; 2013 Dec; 48(3):737-56. PubMed ID: 23636981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
    Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
    J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.
    Comabella M; Lünemann JD; Río J; Sánchez A; López C; Julià E; Fernández M; Nonell L; Camiña-Tato M; Deisenhammer F; Caballero E; Tortola MT; Prinz M; Montalban X; Martin R
    Brain; 2009 Dec; 132(Pt 12):3353-65. PubMed ID: 19741051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Signature's Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients.
    Jabbari S; Hosseinpourfeizi M; Safaralizadeh R; Baradaran B
    Curr Mol Med; 2024; 24(10):1301-1306. PubMed ID: 37842895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis.
    Downer EJ; Clifford E; Gran B; Nel HJ; Fallon PG; Moynagh PN
    J Biol Chem; 2011 Mar; 286(12):10316-28. PubMed ID: 21245146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
    Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
    Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
    Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.
    López-Gómez C; Pino-Ángeles A; Órpez-Zafra T; Pinto-Medel MJ; Oliver-Martos B; Ortega-Pinazo J; Arnáiz C; Guijarro-Castro C; Varadé J; Álvarez-Lafuente R; Urcelay E; Sánchez-Jiménez F; Fernández Ó; Leyva L
    PLoS One; 2013; 8(4):e62540. PubMed ID: 23658636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
    Hecker M; Goertsches RH; Fatum C; Koczan D; Thiesen HJ; Guthke R; Zettl UK
    Pharmacogenomics J; 2012 Apr; 12(2):134-46. PubMed ID: 20956993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel peripheral blood mononuclear cell mRNA signature for IFN-beta therapy responsiveness prediction in multiple sclerosis.
    Xue Y; Yin P; Chen H; Li G; Zhong D
    Autoimmunity; 2024 Dec; 57(1):2332340. PubMed ID: 38545756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?
    Hesse D; Krakauer M; Lund H; Søndergaard HB; Limborg SJW; Soelberg Sørensen P; Sellebjerg F
    Eur J Neurol; 2011 Feb; 18(2):266-272. PubMed ID: 20561040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.
    Khsheibun R; Paperna T; Volkowich A; Lejbkowicz I; Avidan N; Miller A
    PLoS One; 2014; 9(7):e102331. PubMed ID: 25025430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Tanasescu R; Midgley A; Robins RA; Constantinescu CS
    Acta Neurol Scand; 2017 Sep; 136(3):233-238. PubMed ID: 27918083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Monotonically Differentially Expressed Genes for IFN-
    Tian S; Zhang L
    Biomed Res Int; 2019; 2019():5647902. PubMed ID: 31915697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.